Incidence of any serious adverse effects attributable to the administration of corticosteroids · children diagnosed with Kawasaki disease
1 finding from 1 review
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether corticosteroids changes disease‐specific mortality ‐ SJS and TEN (time to compared with no corticosteroids (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue relief ( · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
QoL · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Fatigue relief ( · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Quality of life ( · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Incidence of coronary artery abnormalities · children diagnosed with Kawasaki disease
Corticosteroids probably leads to lower incidence of coronary artery abnormalities compared with no corticosteroid use (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · children diagnosed with Kawasaki disease
1 finding from 1 review
Duration of clinical symptoms: fever and rash (days) · children diagnosed with Kawasaki disease
1 finding from 1 review
Time for laboratory parameters to normalise: CRP, ESR (days) Duration: N/A · children diagnosed with Kawasaki disease
1 finding from 1 review
Length of hospital stay · children diagnosed with Kawasaki disease
1 finding from 1 review